Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

February 12, 2021 Auto Bot Acquire, Agreement, GSK, M&A, Sandoz, Signs 0

Shots:

  • GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21
  • The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches
  • The agreement includes the global rights to three established brands (Zinnat, Zinacef and Fortum) in 100+ markets. Additionally, Sandoz plans to expand its integrated manufacturing site in Kundl with the manufacturing of Zinnat

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Law.com

The post Novartis to Acquire GSK’s Cephalosporin Antibiotics Business first appeared on PharmaShots.